Business
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan Matrix-M adjuvant to be supplied from Novavax
About this update from Novavax, Inc.
[{"type":"text","content":"\n\nNovavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan\n\n\nMatrix-M adjuvant to be supplied from Novavax\n\n\nGovernment of Japan will provide funding to Takeda for technology transfer, establishment of infrastructure and scale-up of manufacturing\n\n\nAdds to Takeda’s ongoing support of influenza pandemic preparedness in Japan\n\n\n GAITHERSBURG, Md. & OSAKA, Japan--(BUSINESS WIRE)--\nNovavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200807005160/en/\n\n“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We look forward to collaborating with Takeda to rapidly develop, produce and commercialize the vaccine in Japan.”\n\n\nNovavax and Takeda are partnering on manufacturing, clinical development and regulatory activities in Japan. Novavax will license and transfer manufacturing technologies to enable Takeda to manufacture the vaccine antigen and will supply the Matrix-M adjuvant to Takeda. Takeda will be responsible for regulatory submission to the MHLW and will produce and distribute NVX‑CoV2373 in Japan.\n\n\n“Nothing is more important right now than protecting the world against COVID-19. We are excited to collaborate with Novavax to bring their promising vaccine candidate to Japan,” said Rajee...